Base de datos : MEDLINE
Búsqueda : B04.820.545.405.400.300 [Categoria DeCS]
Referencias encontradas : 3372 [refinar]
Mostrando: 1 .. 10   en el formato [Largo]

página 1 de 338 va a la página                         

  1 / 3372 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28456530
Autor:Zhang Y; Wu P; Feng L; Yang P; Pan Y; Feng S; Qin Y; Zheng J; Puig-Barberà J; Muscatello D; MacIntyre R; Cowling BJ; Yu H; Wang Q
Dirección:Institute of Infectious Diseases and Endemic Diseases Control, Beijing Center for Disease Prevention and Control, Beijing, China; School of Public Health and Community Medicine, The University of New South Wales, Sydney, NSW 2052, Australia.
Título:Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China.
Fuente:Vaccine; 35(23):3129-3134, 2017 05 25.
ISSN:1873-2518
País de publicación:Netherlands
Idioma:eng
Resumen:BACKGROUND: Vaccination is recommended to prevent influenza virus infection and associated complications. This study aimed to estimate the influenza vaccine effectiveness (VE) against hospitalization in the 2015/16 season in Beijing. METHODS: Patients who were hospitalized in the 5 study hospitals between 1 Oct 2015 and 15 May 2016 were recruited. Influenza vaccination status was obtained for PCR-confirmed influenza patients and the selected controls who tested negative for the virus. Conditional logistic regression was used to estimate the influenza VE matching by calendar week, and adjusting for age, study sites, underlying medical conditions, smoking status, and hospital admissions over the past 12months. RESULTS: The overall VE was -37.9% (95% CI: -103.3, 6.5) against laboratory-confirmed influenza-associated hospitalization. The 2015-16 seasonal vaccine was had -61.9% (95% CI: -211.9, 15.9), -5.4% (95% CI: -108.1, 46.6) and -45.2% (95% CI: -152.6, 16.5) effectiveness to prevent infection from A(H1N1)pdm09, A(H3N2) and influenza B, respectively. CONCLUSIONS: Influenza vaccination did not show effective protection against hospitalization with influenza in 2015/16 season in Beijing.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.; RESEARCH SUPPORT, NON-U.S. GOV'T
Nombre de substancia:0 (Influenza Vaccines)


  2 / 3372 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29212467
Autor:Yu X; Wang C; Chen T; Zhang W; Yu H; Shu Y; Hu W; Wang X
Dirección:Department of Biostatistics, School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, 200231 Xuhui District, Shanghai, China.
Título:Excess pneumonia and influenza mortality attributable to seasonal influenza in subtropical Shanghai, China.
Fuente:BMC Infect Dis; 17(1):756, 2017 12 07.
ISSN:1471-2334
País de publicación:England
Idioma:eng
Resumen:BACKGROUND: Disease burden attributable to influenza is substantial in subtropical regions. Our study aims to estimate excess pneumonia and influenza (P&I) mortality associated with influenza by subtypes/lineages in Shanghai, China, 2010-2015. METHODS: Quasi-Poisson regression models were fitted to weekly numbers of deaths from causes coded as P&I for Shanghai general and registered population. Three proxies for influenza activity were respectively used as an explanatory variable. Long-term trend, seasonal trend and absolute humidity were adjusted for as confounding factors. The outcome measurements of excess P&I mortality associated with influenza subtypes/lineages were derived by subtracting the baseline mortality from fitted mortality. RESULTS: Excess P&I mortality associated with influenza were 0.22, 0.30, and 0.23 per 100,000 population for three different proxies in Shanghai general population, lower than those in registered population (0.34, 0.48, and 0.36 per 100,000 population). Influenza B (Victoria) lineage did not contribute to excess P&I mortality (P = 0.206) while influenza B (Yamagata) lineage did (P = 0.044). Influenza-associated P&I mortality was high in the elderly population. CONCLUSIONS: Seasonal influenza A virus had a higher P&I mortality than influenza B virus, while B (Yamagata) lineage is the dominant lineage attributable to P&I mortality.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T


  3 / 3372 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29202715
Autor:Talla Nzussouo N; Duque J; Adedeji AA; Coulibaly D; Sow S; Tarnagda Z; Maman I; Lagare A; Makaya S; Elkory MB; Kadjo Adje H; Shilo PA; Tamboura B; Cisse A; Badziklou K; Maïnassara HB; Bara AO; Keita AM; Williams T; Moen A; Widdowson MA; McMorrow M
Dirección:Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. tallus5@yahoo.fr.
Título:Epidemiology of influenza in West Africa after the 2009 influenza A(H1N1) pandemic, 2010-2012.
Fuente:BMC Infect Dis; 17(1):745, 2017 12 04.
ISSN:1471-2334
País de publicación:England
Idioma:eng
Resumen:BACKGROUND: Over the last decade, capacity for influenza surveillance and research in West Africa has strengthened. Data from these surveillance systems showed influenza A(H1N1)pdm09 circulated in West Africa later than in other regions of the continent. METHODS: We contacted 11 West African countries to collect information about their influenza surveillance systems (number of sites, type of surveillance, sampling strategy, populations sampled, case definitions used, number of specimens collected and number of specimens positive for influenza viruses) for the time period January 2010 through December 2012. RESULTS: Of the 11 countries contacted, 8 responded: Burkina Faso, Cote d'Ivoire, Mali, Mauritania, Niger, Nigeria, Sierra Leone and Togo. Countries used standard World Health Organization (WHO) case definitions for influenza-like illness (ILI) and severe acute respiratory illness (SARI) or slight variations thereof. There were 70 surveillance sites: 26 SARI and 44 ILI. Seven countries conducted SARI surveillance and collected 3114 specimens of which 209 (7%) were positive for influenza viruses. Among influenza-positive SARI patients, 132 (63%) were influenza A [68 influenza A(H1N1)pdm09, 64 influenza A(H3N2)] and 77 (37%) were influenza B. All eight countries conducted ILI surveillance and collected 20,375 specimens, of which 2278 (11%) were positive for influenza viruses. Among influenza-positive ILI patients, 1431 (63%) were influenza A [820 influenza A(H1N1)pdm09, 611 influenza A(H3N2)] and 847 (37%) were influenza B. A majority of SARI and ILI case-patients who tested positive for influenza (72% SARI and 59% ILI) were children aged 0-4 years, as were a majority of those enrolled in surveillance. The seasonality of influenza and the predominant influenza type or subtype varied by country and year. CONCLUSIONS: Influenza A(H1N1)pdm09 continued to circulate in West Africa along with influenza A(H3N2) and influenza B during 2010-2012. Although ILI surveillance systems produced a robust number of samples during the study period, more could be done to strengthen surveillance among hospitalized SARI case-patients. Surveillance systems captured young children but lacked data on adults and the elderly. More data on risk groups for severe influenza in West Africa are needed to help shape influenza prevention and clinical management policies and guidelines.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.


  4 / 3372 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28592143
Autor:Pang X; Lin X; Tian Y; Liang R; Wang J; Yang B; Zhou X; Kaliyaperumal K; Luo X; Tu Z; Liu Y
Dirección:a CAS Key Laboratory of Tropical Marine Bio-resources and Ecology/Guangdong Key Laboratory of Marine Materia Medica/RNAM Center for Marine Microbiology , South China Sea Institute of Oceanology, Chinese Academy of Sciences , Guangzhou , China.
Título:Three new polyketides from the marine sponge-derived fungus Trichoderma sp. SCSIO41004.
Fuente:Nat Prod Res; 32(1):105-111, 2018 Jan.
ISSN:1478-6427
País de publicación:England
Idioma:eng
Resumen:Three new polyketides named trichbenzoisochromen A (1), 5,7-dihydroxy-3-methyl -2-(2-oxopropyl)naphthalene-1,4-dione (2) and 7-acetyl-1,3,6-trihydroxyanthracene-9,10- dione (3) together with six known compounds (4-9) were isolated from a sponge-derived fungus Trichoderma sp. SCSIO41004. The structures of three new polyketides (1-3) were determined by the extensive spectroscopic analysis, including 1D, 2D NMR and HRESIMS data. The absolute configuration of compound 1 was confirmed by the specific optical rotation value and CD spectra analyses. Compound 4 exhibited significant inhibitory activity against EV71 with the IC value of 25.7 µM.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Anthracenes); 0 (Antiviral Agents); 0 (Naphthalenes); 0 (Polyketides)


  5 / 3372 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29447145
Autor:Budd AP; Wentworth DE; Blanton L; Elal AIA; Alabi N; Barnes J; Brammer L; Burns E; Cummings CN; Davis T; Flannery B; Fry AM; Garg S; Garten R; Gubareva L; Jang Y; Kniss K; Kramer N; Lindstrom S; Mustaquim D; O'Halloran A; Olsen SJ; Sessions W; Taylor C; Xu X; Dugan VG; Katz J; Jernigan D
Dirección:Influenza Division, National Center for Immunization and Respiratory Diseases, CDC.
Título:Update: Influenza Activity - United States, October 1, 2017-February 3, 2018.
Fuente:MMWR Morb Mortal Wkly Rep; 67(6):169-179, 2018 Feb 16.
ISSN:1545-861X
País de publicación:United States
Idioma:eng
Resumen:Influenza activity in the United States began to increase in early November 2017 and rose sharply from December through February 3, 2018; elevated influenza activity is expected to continue for several more weeks. Influenza A viruses have been most commonly identified, with influenza A(H3N2) viruses predominating, but influenza A(H1N1)pdm09 and influenza B viruses were also reported. This report summarizes U.S. influenza activity* during October 1, 2017-February 3, 2018, and updates the previous summary (1).
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Antiviral Agents)


  6 / 3372 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29447141
Autor:Flannery B; Chung JR; Belongia EA; McLean HQ; Gaglani M; Murthy K; Zimmerman RK; Nowalk MP; Jackson ML; Jackson LA; Monto AS; Martin ET; Foust A; Sessions W; Berman L; Barnes JR; Spencer S; Fry AM
Título:Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.
Fuente:MMWR Morb Mortal Wkly Rep; 67(6):180-185, 2018 Feb 16.
ISSN:1545-861X
País de publicación:United States
Idioma:eng
Resumen:In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months (1). During each influenza season since 2004-05, CDC has estimated the effectiveness of seasonal influenza vaccine to prevent laboratory-confirmed influenza associated with medically attended acute respiratory illness (ARI). This report uses data from 4,562 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network (U.S. Flu VE Network) during November 2, 2017-February 3, 2018. During this period, overall adjusted vaccine effectiveness (VE) against influenza A and influenza B virus infection associated with medically attended ARI was 36% (95% confidence interval [CI] = 27%-44%). Most (69%) influenza infections were caused by A(H3N2) viruses. VE was estimated to be 25% (CI = 13% to 36%) against illness caused by influenza A(H3N2) virus, 67% (CI = 54%-76%) against A(H1N1)pdm09 viruses, and 42% (CI = 25%-56%) against influenza B viruses. These early VE estimates underscore the need for ongoing influenza prevention and treatment measures. CDC continues to recommend influenza vaccination because the vaccine can still prevent some infections with currently circulating influenza viruses, which are expected to continue circulating for several weeks. Even with current vaccine effectiveness estimates, vaccination will still prevent influenza illness, including thousands of hospitalizations and deaths. Persons aged ≥6 months who have not yet been vaccinated this season should be vaccinated.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Influenza Vaccines)


  7 / 3372 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:27771390
Autor:Smee DF; Barnard DL; Jones SM
Dirección:Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT 84322-5600, USA. Electronic address: don.smee@usu.edu.
Título:Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
Fuente:Antiviral Res; 136:45-50, 2016 12.
ISSN:1872-9096
País de publicación:Netherlands
Idioma:eng
Resumen:JNJ63623872 (formerly known as VX-787) is an inhibitor of influenza A virus polymerases through interaction with the viral PB2 subunit. This interaction blocks the cap-snatching activity of the virus that is essential for virus replication. Previously published work has documented antiviral activity of JNJ63623872 in cell culture and mouse infection studies. In this report, we extend the in vivo observations by comparing the efficacies of JNJ63623872 and oseltamivir in mice infected with influenza A/California/04/2009 (H1N1pdm) and A/Victoria/3/75 (H3N2) viruses. Animals received JNJ63623872 or oseltamivir orally twice daily for 10 days starting 2 h pre-infection. JNJ63623872 (2, 6, and 20 mg/kg/day) and oseltamivir (20 mg/kg/day) completely prevented death in the H1N1pdm virus infection. Weight loss at nadir was only 12% in mice receiving 2 mg/kg/day of JNJ63623872 compared to 23% and 32%, respectively, in oseltamivir-treated (20 mg/kg/day) and placebo groups. Lung hemorrhage scores, lung weights, and lung virus titers on day 6 were reduced in a dose-responsive manner by JNJ63623872 treatments, whereas oseltamivir treatments were not as effective. JNJ63623872 was less active against H3N2 virus infection, with more body weight loss occurring and only 30% survival at the 2-mg/kg/day dose. Lung scores, lung weights, and H3N2 viral titers in lungs of mice were reduced less by JNJ63623872 treatments compared to the H1N1pdm infection. Nevertheless, the 20-mg/kg/day dose of JNJ63623872 was more effective than oseltamivir (20 mg/kg/day) in improving body weight and reducing the severity of lung infection. JNJ63623872 appears to be an important new drug candidate to treat influenza A H1N1pdm and H3N2 virus infections.
Tipo de publicación:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
Nombre de substancia:0 (Antiviral Agents); 0 (Indoles); 0 (VX-787); 20O93L6F9H (Oseltamivir)


  8 / 3372 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PMID:29210538
Autor:Ikematsu H; Chong Y; Shirane K; Toh H; Sasaki H; Matsumoto S; Noda N; Hotta T; Uchiumi T; Kang D
Título:Neuraminidase Amino Acid Sequences of Influenza A/H3N2 and B Viruses Isolated from Influenza Patients in the 2014/15 Japanese Influenza Season.
Fuente:Fukuoka Igaku Zasshi; 107(5):98-104, 2016 05.
ISSN:0016-254X
País de publicación:Japan
Idioma:jpn
Resumen:Background: Neuraminidase (NA) is a surface protein essential for influenza virus replication. NA inhibitors are commonly used for the treatment of influenza patients in Japan. Several mutations that reduce the effect of NA inhibitors have been reported. We sequenced the whole NA segment of isolated virus from influenza patients and investigated the relation between the NA amino acid sequence and the 50ï¼… inhibitory concentration (IC_50) of four NA inhibitors. Materials and Methods: Forty A/H3N2 and 19 B influenza virus isolated from patients in the 2014/15 influenza season were analyzed. The IC_50 was determined by a neuraminidase inhibition assay using a fluorescent substrate. Viral RNA was amplified by RT-PCR and the genome was sequenced using a next generation sequencer. The deduced amino acid sequences were analyzed. Results: There was no AA change in the NA catalytic site of the A/H3N2 and B viruses isolated in the 2014-15 influenza season. There was no significant relation between the NA amino acids and the IC_50 of the four NA inhibitors for A/H3N2 or B viruses. Conclusion: The catalytic site of NA was highly conserved for these A/H3N2 and B viruses. No emergence of NA amino acid mutations related to the sensitivity of the four currently used NA inhibitors was observed.
Tipo de publicación:JOURNAL ARTICLE; ENGLISH ABSTRACT
Nombre de substancia:EC 3.2.1.18 (Neuraminidase)


  9 / 3372 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29324805
Autor:Lee YT; Ko EJ; Lee Y; Kim KH; Kim MC; Lee YN; Kang SM
Dirección:Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, United States of America.
Título:Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
Fuente:PLoS One; 13(1):e0190868, 2018.
ISSN:1932-6203
País de publicación:United States
Idioma:eng
Resumen:Current influenza vaccines do not provide broad cross-protection. Here, we report that intranasal vaccination with virus-like particles containing the highly conserved multiple ectodomains of matrix protein 2 (M2e5x VLP) of influenza virus induces broad cross-protection by M2-specific humoral and cellular immune responses. M2e5x VLP intranasal vaccination prevented severe weight loss, attenuated inflammatory cytokines and cellular infiltrates, and lowered viral loads, and induced germinal center phenotypic B and plasma cells. In addition, depletion studies demonstrate the protective roles of CD4 and CD8 T cells induced by M2e5x VLP intranasal vaccination. Thus, this study provides evidence that mucosal delivery of M2e5x VLP vaccine provides cross-protection by inducing humoral and cellular immune responses.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
Nombre de substancia:0 (Antibodies, Viral); 0 (Influenza Vaccines); 0 (Vaccines, Virus-Like Particle); 0 (Viral Matrix Proteins)


  10 / 3372 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29324781
Autor:Tewawong N; Marathe BM; Poovorawan Y; Vongpunsawad S; Webby RJ; Govorkova EA
Dirección:Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Título:Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
Fuente:PLoS One; 13(1):e0190877, 2018.
ISSN:1932-6203
País de publicación:United States
Idioma:eng
Resumen:Amino acid substitutions within or near the active site of the viral neuraminidase (NA) may affect influenza virus fitness. In influenza A(H3N2) and B viruses circulating in Thailand between 2010 and 2015, we identified several NA substitutions that were previously reported to be associated with reduced inhibition by NA inhibitors (NAIs). To study the effect of these substitutions on the enzymatic properties of NA and on virus characteristics, we generated recombinant influenza viruses possessing either a wild type (WT) NA or an NA with a single I222V, S331G, or S331R substitution [in influenza A(H3N2) viruses] or a single D342S, A395T, A395V, or A395D NA substitution (in influenza B viruses). We generated recombinant (7:1) influenza A and B viruses on the genetic background of A/Puerto Rico/8/1934 (A/PR/8, H1N1) or B/Yamanashi/166/1998 (B/YAM) viruses, respectively. In contrast to the expected phenotypes, all the recombinant influenza A(H3N2) and B viruses carrying putative NA resistance substitutions were susceptible to NAIs. The Km and Vmax for the NAs of A/PR8-S331G and A/PR8-S331R viruses were higher than for the NA of WT virus, and the corresponding values for the B/YAM-D342S virus were lower than for the NA of WT virus. Although there was initial variation in the kinetics of influenza A and B viruses' replication in MDCK cells, their titers were comparable to each other and to WT viruses at later time points. All introduced substitutions were stable except for B/YAM-D342S and B/YAM-A395V which reverted to WT sequences after three passages. Our data suggest that inferring susceptibility to NAIs based on sequence information alone should be cautioned. The impact of NA substitution on NAI resistance, viral growth, and enzymatic properties is viral context dependent and should be empirically determined.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
Nombre de substancia:0 (Antiviral Agents); 0 (Enzyme Inhibitors); 0 (Viral Proteins); EC 3.2.1.18 (Neuraminidase)



página 1 de 338 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud